NEXTBio Capital Management LP 13F holdings, Q1 2026
Holdings as of March 31, 2026 · filings on SEC EDGAR · latest filing →
NEXTBio Capital Management LP disclosed 24 US equity positions worth $215.4m in its Q1 2026 13F filing. The largest position was 430 at 14.8% of the reported book, followed by PTGX and STTK.
What did NEXTBio Capital Management LP own in Q1 2026? Top 24 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | 430 TERNS PHARMACEUTICALS INC | 14.8% | $31.9m | 604,534 | – | ||
| 2 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 11.2% | $24.2m | 229,619 | – | |
| 3 | STTK SHATTUCK LABS INC | Healthcare | 9.4% | $20.3m | 3,149,907 | – | |
| 4 | VOR VOR BIOPHARMA INC | Healthcare | 8.3% | $17.8m | 999,967 | – | |
| 5 | CMPS COMPASS PATHWAYS PLC | Healthcare | 5.2% | $11.2m | 2,021,407 | – | |
| 6 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 5.1% | $11.0m | 126,078 | – | |
| 7 | XENE XENON PHARMACEUTICALS INC | Healthcare | 4.9% | $10.7m | 183,225 | – | |
| 8 | PVLA PALVELLA THERAPEUTICS INC NE | Healthcare | 4.8% | $10.3m | 82,686 | – | |
| 9 | ZBIO ZENAS BIOPHARMA INC | 3.9% | $8.3m | 426,736 | – | ||
| 10 | IVA INVENTIVA SA | 3.4% | $7.4m | 1,333,484 | – | ||
| 11 | VSTM VERASTEM INC | Healthcare | 3.2% | $6.9m | 1,306,800 | – | |
| 12 | CBIO CRESCENT BIOPHARMA INC. | 3.2% | $6.8m | 372,856 | – | ||
| 13 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 3.1% | $6.6m | 523,619 | – | |
| 14 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 3.0% | $6.4m | 133,239 | – | |
| 15 | PCVX VAXCYTE INC | Healthcare | 2.6% | $5.5m | 95,223 | – | |
| 16 | COGT COGENT BIOSCIENCES INC | Healthcare | 2.3% | $5.0m | 131,188 | – | |
| 17 | CMPX COMPASS THERAPEUTICS INC | 2.1% | $4.5m | 848,204 | – | ||
| 18 | EVMN EVOMMUNE INC | 2.0% | $4.2m | 184,063 | – | ||
| 19 | OCULIS HOLDING AG | 1.8% | $4.0m | 149,592 | – | ||
| 20 | ZLAB ZAI LAB LTD | Healthcare | 1.6% | $3.4m | 183,362 | – | |
| 21 | IRON DISC MEDICINE INC | Healthcare | 1.6% | $3.4m | 52,655 | – | |
| 22 | 4XC1 KALVISTA PHARMACEUTICALS INC | 1.2% | $2.7m | 131,796 | – | ||
| 23 | SMMT SUMMIT THERAPEUTICS INC | Healthcare | 0.8% | $1.7m | 89,717 | – | |
| 24 | ACET ADICET BIO INC | 0.5% | $1.1m | 157,827 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.